Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study

Mark N. Gaze, Daria Handkiewicz-Junak, Raquel Hladun, Theodore W. Laetsch, Caryn Sorge, Richard Sparks, Simon Wan, Antony Ceraulo, Aneta Kluczewska-Gałka, Cristina Gámez‐Cenzano, Lisa J. States, Riham El Khouli, Paola Aimone, Kevin Perraud, Gabor Kollar, Fariba Khanshan, Lars Blumenstein, Fazia Brouri, Anne‐Laure Giraudet